Segmentation validation dataset
120 cases
- Endpointvalidation dataset size
- PopulationKorean and U.S. CT cases across breast, head and neck, abdomen, and pelvis organ sets
- Tested versionAVIEW RT ACS (K220408)
FDA-cleared profile
Coreline Soft Co.,Ltd · Radiotherapy Planning Imaging · FDA-cleared (510(k))
Authorized purpose: AVIEW RT ACS is a medical image-management and processing system for radiation-treatment planning with deep-learning auto-segmentation evidence described in the exact FDA decision material; the submission compares automated organ segmentation with a predicate using Dice similarity coefficient and 95% Hausdorff distance on CT cases.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: AVIEW RT ACS is a medical image-management and processing system for radiation-treatment planning with deep-learning auto-segmentation evidence described in the exact FDA decision material; the submission compares automated organ segmentation with a predicate using Dice similarity coefficient and 95% Hausdorff distance on CT cases.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA material describes a 120-case Korean and U.S. CT validation dataset reviewed with a three-physician radiation-oncology gold-standard process across breast, head and neck, abdomen, and pelvis organ sets; reported endpoints include DSC and 95% Hausdorff distance.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
120 cases
K220408
The exact FDA material describes a 120-case Korean and U.S. CT validation dataset reviewed with a three-physician radiation-oncology gold-standard process across breast, head and neck, abdomen, and pelvis organ sets; reported endpoints include DSC and 95% Hausdorff distance.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-04 · FDA 510(k) decision material K220408: AVIEW RT ACS
Source context, not route validation: The exact FDA material lists DICOM testing, a DICOM conformance statement, and thin-client/server compatibility testing; exact local interfaces, identity, routing, and treatment-planning integration require validation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 · FDA 510(k) decision material K220408: AVIEW RT ACS
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Source context, not route validation: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-04 · FDA 510(k) decision material K220408: AVIEW RT ACS
Unresolved route: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-04 · FDA 510(k) decision material K220408: AVIEW RT ACS
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Radiation-treatment planning, image registration, contouring, dose calculation, or plan review support under qualified professional control.
exact submission · checked 2026-09-04Submission-anchored workflow summary, not a local acceptance or deployment result.
Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.
exact submission · checked 2026-09-04Exact supported inputs and protocol limits must be confirmed from the complete labeling.
Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
exact submission · checked 2026-09-04Output review, editing, approval, export, and downstream use remain release- and site-specific.
Exact deployment topology and operational boundaries remain unestablished.
exact submission · checked 2026-09-04Confirm hosting, PHI flow, retention, access, updates, downtime, and support obligations before procurement or clinical use.
The exact FDA material lists DICOM testing, a DICOM conformance statement, and thin-client/server compatibility testing; exact local interfaces, identity, routing, and treatment-planning integration require validation.
exact submission · checked 2026-09-04Validate the local workflow against the exact release and enabled options.
Current vendor material is product-family context for K220408 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04Vendor material is not exact-release evidence unless that linkage is separately proven.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.
Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
8 sources - 3 history items
Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Scope: reimbursement, radiationTherapyPaymentContext
Scope: productFamilyContext
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
MVision AI
Authorized purpose: MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Wisdom Technologies., Inc.
Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.
RaySearch Laboratories AB (publ)
Authorized purpose: RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.
Microsoft Corp.
Authorized purpose: Microsoft Radiomics App v1.0 is a software-only medical device for trained radiation oncologists, dosimetrists, and physicists to derive organ and tumor contours for radiation-treatment planning. It supports CT and MR images, image and contour review, contour creation and modification, transfer to treatment-planning systems, adaptive-therapy support, archiving, tumor and healthy-structure localization, image fusion, and three-dimensional rendering. Images reviewed with the software should not be used for primary image interpretations, and it is not for digital mammography.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history